Fractional flow reserve (FFR) is a well-established method of assessing haemodynamically significant coronary artery stenoses that has demonstrated improved outcomes when used to guide revascularization decisions in patients with stable coronary artery disease. However, the role of FFR in the setting of acute coronary syndrome (ACS) remains uncertain. The recently published FAMOUS-NSTEMI trial was a pilot study that demonstrated the safety of routine FFR in ACS patients as well as its impact upon refining management decisions in patients with stenoses of varying severity in nonculprit arteries. The goal of this review is to summarize the current literature of the utility of FFR in the ACS population and highlight the role that the results of FAMOUS-NSTEMI may have on future study and management in this area.